Medical News

RSS

Feihe International fourth quarter sales increase 42.1% to $87.0M

Feihe International, Inc., one of the leading producers and distributors of premium infant formula, milk powder and soybean, rice and walnut products in China, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2011.

31 Mar 2012

Elective endovascular aneurysm repair benefits men more than women

A study published in the April issue of Journal of Vascular Surgery reports that women derive less benefit than men from elective endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA's). The research was done at The Vascular Group, The Institute for Vascular Health and Disease, Albany Medical College, The Center for Vascular Awareness Inc., in Albany, NY.

31 Mar 2012

Modern delivery practices contribute to increase in labor duration

Women take longer to give birth today than did women 50 years ago, according to an analysis of nearly 140,000 deliveries conducted by researchers at the National Institutes of Health. The researchers could not identify all of the factors that accounted for the increase, but concluded that the change is likely due to changes in delivery room practice.

31 Mar 2012

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2011.

31 Mar 2012

Starvation during childhood may increase risk of heart complications

Russians born during the Leningrad Siege in World War II, which was responsible for some of the greatest losses of civilian life in history, are giving scientists new strategies to identify people who experienced intrauterine growth restriction (IUGR) and starvation during childhood at greatest risk of developing long term heart complications.

31 Mar 2012

Canadian regulatory body recommendation brings melanoma patients closer to life-extending drugs

The Melanoma Network of Canada is pleased that the Canadian regulatory body, pCODR (pan-Canadian Oncology Drug Review) has made an initial recommendation that includes positive clinical evaluations for the latest treatments for metastatic melanoma.

31 Mar 2012

Disaster survivors to benefit from new agreement between Rotary International, ShelterBox

Survivors of natural disasters worldwide will benefit from a new agreement between the humanitarian service organization Rotary International and the disaster relief charity ShelterBox that leverages the strengths of both organizations to provide temporary shelters and critically needed supplies to displaced families quickly and efficiently.

31 Mar 2012

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Cortex reports net income of $832,000 for fourth quarter 2011

Cortex Pharmaceuticals, Inc. reported net income of approximately $832,000, or $0.01 per share, for the quarter ended December 31, 2011, compared with a net loss of approximately $984,000, or $0.01 per share, for the corresponding prior year quarter.

31 Mar 2012

Number of kidney cancer cases rises over 9,000 in Great Britain

The number of cases of kidney cancer diagnosed each year in Great Britain has risen over 9,000 for the first time, new figures from Cancer Research UK show today.

31 Mar 2012

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo.

31 Mar 2012

Nile Therapeutics to sell 3.6 million shares of common stock

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive agreement to sell 3.6 million shares of its common stock at a price per share of $0.40 for aggregate gross proceeds of $1.44 million.

31 Mar 2012

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.

31 Mar 2012

China Shenghuo 2011 total revenue increases 35% to $44.2 million

China Shenghuo Pharmaceutical Holdings, Inc., today reported financial results for the year ended December 31, 2011.

31 Mar 2012

Teva introduces generic Provigil

Teva Pharmaceutical Industries Ltd. announces the launch of the authorized generic of Provigil (modafinil).

31 Mar 2012

Economics lessons for the court: Broccoli isn't the same as health care

Given the stakes, one might have expected all the court's members to be very careful in speaking about both health care realities and legal precedents. In reality, however, the second day of hearings suggested that the justices most hostile to the law don't understand, or choose not to understand, how insurance works.

31 Mar 2012

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Accuray Incorporated, the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city's top international position in therapy, research and science.

31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

Differentiating between sneezing due to cold and allergies

One of the problems that parents may have during the springtime is deciphering whether their children's sneezing is due to a cold or allergies.

31 Mar 2012

Mirada Medical, BioClinica partner to extend oncology clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada's XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

From Clario 31 Mar 2012